

Scientific Programme

11.10.2020

Lower GI Live Symposium Hall 1 09:00 – 10:00 CEST

Faecal microbiota transplantation (FMT): Where do we stand in 2020?

Chair: J. Kupcinkas, Lithuania

Chair: B.H. Mullish, United Kingdom

IP008	Rising Star: The future of faecal microbial transplantation: From FMT to future microbiota G. Ianaro, Italy	09:00 CEST
	Q&A	09:10 CEST
IP009	Early life microbiome: A risk factor! L.R. Lopetuso, Italy	09:20 CEST
	Q&A	09:30 CEST
IP010	The role of FMT in ulcerative colitis C.Y. Ponsioen, Netherlands	09:40 CEST
	Q&A	09:50 CEST

Upper GI Moderated Poster Hall 5 12:00 – 13:00 CEST

Gastro-intestinal functional disorders

Chair: H. Törnblom, Sweden

Chair: R. Sweis, United Kingdom

P0055	TRANSCUTANEOUS VAGAL NERVE STIMULATION AS A POTENTIAL TREATMENT FOR FUNCTIONAL GASTROINTESTINAL DISORDERS: A META-ANALYSIS OF NEUROIMAGING EVIDENCE R. Rajiah, United Kingdom	
	Q&A	
P0051	GASTRIC EMPTYING TIME USING SMARTPILL WIRELESS MOTILITY CAPSULE CORRELATES WITH HUNGER CONTRACTIONS AND HIGH GHRELIN M.-U. Din, Sweden	
	Q&A	
P0044	FUNCTIONAL DYSPESIA AND ITS SUBGROUPS: PREVALENCE AND IMPACT IN THE ROME IV GLOBAL EPIDEMIOLOGY STUDY J. Tack, Belgium	
	Q&A	
P0048	DIFFERENTIAL EFFECTS OF DUODENAL BILE SALTS ON MUCOSAL PHYSIOLOGY AND SYMPTOMS IN FUNCTIONAL DYSPESIA PATIENTS M. Ceulemans, Belgium	
	Q&A	
P0256	SMALL INTESTINAL BACTERIAL OVERGROWTH REMISSION AND SYMPTOMS IMPROVEMENT AFTER ANTIBIOTIC TREATMENT: A FRENCH RETROSPECTIVE COMPARATIVE STUDY N. Richard, France	
	Q&A	
	Panel discussion	

IBS I

Chair: D.L. Dumitrascu, Romania

Chair: M. Simrén, Sweden

OP056	IMPACT OF PRENATAL STRESS ON VISCERAL SENSITIVITY AND INTESTINAL HOMEOSTASIS IN ADULTHOOD C. Petitfils, France	18:00 CEST
	Q&A	18:07 CEST
OP057	EARLY RESPONSE TO PLECANATIDE PREDICTS OVERALL AND SUSTAINED EFFICACY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION E.M. Quigley, United States	18:12 CEST
	Q&A	18:19 CEST
OP058	EXPRESSION AND LOCALIZATION OF CANNABINOID RECEPTORS AND THE EFFECT OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2, ON VISCERAL HYPERSENSITIVITY IN RODENT MODELS OF IRRITABLE BOWEL SYNDROME AND INFLAMMATORY BOWEL DISEASE J. Castro, Australia	18:24 CEST
	Q&A	18:31 CEST
OP059	LONG-TERM EFFECTS OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) IN PATIENTS WITH IRRITABLE BOWEL SYNDROME M. El-Salhy, Norway	18:36 CEST
	Q&A	18:43 CEST
OP060	EFFECTS OF ELUXADOLINE TREATMENT ON ABDOMINAL AND BOWEL SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA REPORTING INADEQUATE SYMPTOM CONTROL WITH LOPERAMIDE: AGGREGATED RESULTS FROM PHASE 3 AND 4 CLINICAL TRIALS L. Liu, Canada	18:48 CEST
	Q&A	18:55 CEST

12.10.2020

Lower GI Live Symposium Hall 1 10:30 – 11:30 CEST

Irritable bowel syndrome (IBS): What's hot in 2020?

Chair: C. Melchior, France

Chair: R. Spiller, United Kingdom

IP105	Current view on IBS pathophysiology: A disorder of gut-brain interaction M. Simrén, Sweden	10:30 CEST
	Q&A	10:40 CEST
IP106	Dietary management of IBS S. Störsrud, Sweden	10:50 CEST
	Q&A	11:00 CEST
IP107	Pharmacology: What's in the pipeline for IBS? J. Tack, Belgium	11:10 CEST
	Q&A	11:20 CEST

The difficult oesophageal patient

Chair: R.S. Penagini, Italy

Chair: A. Smout, Netherlands

IP111	Functional oropharyngeal and oesophageal dysphagia N. Rommel, Belgium	10:30 CEST
	Q&A	10:40 CEST
IP112	Belching D. Sifrim, United Kingdom	10:50 CEST
	Q&A	11:00 CEST
IP113	Chest pain E.V. Savarino, Italy	11:10 CEST
	Q&A	11:20 CEST

IBS I

Chair: M. Rajilic-Stojanovic, Serbia

P0769	BEYOND ROME IV; CAN NALDEMEDINE CHANGE EXPECTATIONS OF TREATMENT RESPONSE IN OPIOID INDUCED CONSTIPATION? P. Conway, United Kingdom	
	Q&A	
P0743	INTAKE OF A PROBIOTIC MIXTURE INCLUDING <i>BIFIDOBACTERIUM LONGUM</i>, <i>LACTOBACILLUS HELVETICUS</i> AND <i>LACTOBACILLUS PLANTARUM</i> AFFECTS BRAIN ACTIVITY AND STRESS RESPONSE IN HEALTHY SUBJECTS: POTENTIAL IMPACT ON GUT-BRAIN AXIS DISORDERS J. Rode, Sweden	
	Q&A	
P0786	PREDICTORS OF TREATMENT RESPONSE TO THE LOW FODMAP AND THE TRADITIONAL DIET IN PATIENTS WITH IRRITABLE BOWEL SYNDROME E. Colomier, Belgium	
	Q&A	
	Panel discussion	

IBS II

Chair: C. Melchior, France

Chair: D. Pohl, Switzerland

P0777	DAILY SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A 2-WEEK PROSPECTIVE HOURLY EVALUATION J. Pannemans, Belgium This abstract will be published on October 11, 2020	
	Q&A	
P0751	ASSESSMENT OF ASCENDING COLONIC DISTENSION FOLLOWING INTRAGASTRIC ADMINISTRATION OF FRUCTANS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME VERSUS HEALTHY CONTROLS: A DOUBLE-BLIND RANDOMISED CONTROL TRIAL COMBINING GASTROINTESTINAL AND BRAIN IMAGING H. Fitzke, United Kingdom	
	Q&A	

P0792 **SYSTEMATIC REVIEW WITH META-ANALYSIS OF LUBIPROSTONE FOR PATIENTS WITH CONSTIPATION**
M.C.F. Passos, Brazil

Q&A

P0789 **EFFICACY OF RIFAXIMIN ON BLOATING IN PATIENTS WITH DIARRHOEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: A POOLED ANALYSIS OF THREE PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIALS**
B. Lacy, United States

Q&A

P0745 **GENOME-WIDE ANALYSIS OF 53,400 PEOPLE WITH IRRITABLE BOWEL SYNDROME HIGHLIGHTS SHARED PATHWAYS WITH NEUROAFFECTIVE TRAITS**
C. Eijsbouts, United Kingdom

Q&A

Panel discussion

Lower GI Live Abstract-based Session Hall 1 18:00 – 19:00 CEST

IBS II

Chair: O.H. Gilja, Norway

Chair: H.F. Hammer, Austria

OP131 **ANAL SLOW WAVE ACTIVITY IN HEALTH AND FAECAL INCONTINENCE** 18:00 CEST
A. Rasijeff, United Kingdom

Q&A 18:07 CEST

OP132 **TOPOGRAPHICAL DISTRIBUTION OF MICROSCOPIC COLITIS, NUMBER OF BIOPSIES NECESSARY FOR DIAGNOSIS, AND IMPORTANCE OF ORIENTATION OF PARAFFIN EMBEDDED BIOPSIES** 18:12 CEST
L.K. Munck, Denmark

Q&A 18:19 CEST

OP133 **FASTING SERUM C4 COMBINED WITH PRIMARY FECAL BILE ACIDS FROM A SINGLE STOOL SAMPLE IS ABLE TO DIAGNOSE PATIENTS WITH BILE ACID DIARRHEA** 18:24 CEST
M. Camilleri, United States

Q&A 18:31 CEST

OP134 **ALLERGY-RELATED DISEASES DURING CHILDHOOD AND RISK OF IRRITABLE BOWEL SYNDROME AT 16 YEARS: A SWEDISH BIRTH COHORT STUDY** 18:36 CEST
J. Sjölund, Sweden

Q&A 18:43 CEST

OP135 **PREVALENCE AND IMPACT OF OVERLAPPING ROME IV DISORDERS OF GUT-BRAIN INTERACTIONS: RESULTS OF A GLOBAL EPIDEMIOLOGY STUDY** 18:48 CEST
A.D. Sperber, Israel

Q&A 18:55 CEST

Coeliac and non coeliac gluten sensitivity

Chair: K. Kurppa, Finland

Chair: C. Cellier, France

IP165	New insights into pathogenesis of coeliac disease	18:00 CEST
	Q&A	18:10 CEST
IP166	Non coeliac gluten sensitivity R. De Giorgio, Italy	18:20 CEST
	Q&A	18:30 CEST
IP167	Refractory coeliac disease and lymphoma K.E. Lundin, Norway	18:40 CEST
	Q&A	18:50 CEST

13.10.2020**Microbiota**

Chair: M. Joossens, Belgium

Chair: A. Stallmach, Germany

OP176	GLUTEN-FREE DIET INFLUENCES THE HUMAN GUT VIROME COMPOSITION S. Garmaeva, Netherlands	13:30 CEST
	Q&A	13:37 CEST
OP177	THE ROLE OF THE GUT MICROBIOME IN MEDIATING LACTOSE INTOLERANCE SYMPTOMS M.D.F. Brandao Gois, Netherlands	13:42 CEST
	Q&A	13:49 CEST
OP178	THE DUTCH MICROBIOME PROJECT: DEFINING THE (UN)HEALTHY GUT MICROBIOME AND ITS DETERMINING FACTORS IN 9000 METAGENOMES R. Gacesa, Netherlands	13:54 CEST
	Q&A	14:01 CEST
OP179	LIFELINES NEXT PILOT: EARLY DEVELOPMENT OF THE GUT BACTERIOME AND VIROME AND THEIR INTERACTIONS T. Sinha, Netherlands	14:06 CEST
	Q&A	14:13 CEST
OP180	DISRUPTION OF THE GUT MICROBIOME IN RENAL TRANSPLANT RECIPIENTS: RESULTS FROM THE TRANSPLANTLINES COHORT AND BIOBANK STUDY J.C. Swarte, Netherlands	14:18 CEST
	Q&A	14:25 CEST

Nausea and vomiting

Chair: H. Heinrich, Switzerland

Chair: R. Sweis, United Kingdom

IP207	Work up of nausea and vomiting R. Tutuian, Switzerland	13:30 CEST
	Q&A	13:40 CEST
IP208	Eating disorders and avoidant/restrictive food intake disorder (ARFID) P. Déchelotte, France	13:50 CEST
	Q&A	14:00 CEST
IP209	European guideline on functional dyspepsia and gastroparesis – UEG and ESNM clinical management guideline J. Tack, Belgium	14:10 CEST
	Q&A	14:20 CEST

Improving diagnosis and treatment of GORD

Chair: D. Sifrim, United Kingdom

Chair: F. Zerbib, France

OP191	UTILITY OF ROUTINE ESOPHAGEAL BIOPSIES IN PATIENTS WITH REFRACTORY REFLUX SYMPTOMS R. Oude Nijhuis, Netherlands	13:30 CEST
	Q&A	13:37 CEST
OP192	ACCURACY OF THE PPI TEST FOR GASTRO-ESOPHAGEAL REFLUX DISEASE DIAGNOSIS: COMPARISON WITH OBJECTIVE WIRELESS PH STUDY DATA R.-I. Rusu, United Kingdom	13:42 CEST
	Q&A	13:49 CEST
OP193	EFFECTIVENESS OF A NOVEL MEDICAL DEVICE CONTAINING HYALURONIC ACID, ALGINATE AND CAMELLIA SINENSIS EXTRACT, FOR THE TREATMENT OF LARYNGOPHARYNGEAL REFLUX SYMPTOMS E.V. Savarino, Italy	13:54 CEST
	Q&A	14:01 CEST
OP194	LOW-FODMAPS DIET FOR THE TREATMENT OF REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE. A RANDOMIZED CONTROLLED TRIAL F. Zerbib, France	14:06 CEST
	Q&A	14:13 CEST
OP195	PNEUMATIC DILATION FOR PERSISTENT DYSPHAGIA AFTER ANTIREFLUX SURGERY, A MULTICENTER RANDOMIZED SHAM-CONTROLLED CLINICAL TRIAL J.M. Schuitemaker, Netherlands	14:18 CEST
	Q&A	14:25 CEST

Basic research on gastrointestinal epithelium

Chair: G.E. Boeckxstaens, Belgium

Chair: M. Mahé, France

P0052 **SACCHAROMYCES BOULARDII CNCM I-745 IMPROVES GUT-BRAIN AXIS DYSFUNCTION IN A HUMANIZED MOUSE MODEL OF IBS WITH CO-MORBID ANXIETY**
M. Constante, Canada

Q&A

P0165 **NOVEL METAL-FREE CARBON MONOXIDE-RELEASING PRODRUG IN PREVENTION OF GASTRIC MUCOSA AGAINST NSAIDS-INDUCED GASTROTOXICITY**
M. Magierowski, Poland

Q&A

P0005 **MITOCHONDRIA-TARGETING HYDROGEN SULFIDE-RELEASING AP-39 IN PREVENTION OF CHEMICALLY-INDUCED GASTRIC MUCOSAL DAMAGE**
D. Bakalarz, Poland

Q&A

Panel discussion

Microbiome and intestinal epithelium

Chair: G.E. Boeckxstaens, Belgium

Chair: M. Sällberg Chen, Sweden

OP201 **THE GUT MICROBIOME FOLLOW-UP ANALYSIS REVEALS ITS FINGERPRINT POTENTIAL AND CLINICAL RELEVANCE** 16:30 CEST
L. Chen, Netherlands

Q&A 16:37 CEST

OP202 **GPR35 SIGNALING IN EPITHELIAL CELLS FACILITATES GOBLET CELLS MATURATION AND LIMITS *CITROBACTER RODENTIUM*-INDUCED COLITIS** 16:42 CEST
H. Melhem, Switzerland

Q&A 16:49 CEST

OP203 **ROLE OF DNA METHYLTRANSFERASE 3A (DNMT3A) IN INTESTINAL EPITHELIAL CELLS DURING HOMEOSTASIS AND INFLAMMATION** 16:54 CEST
A. Fazio, Germany

Q&A 17:01 CEST

OP204 **AN AUTOPHAGY PROTEIN ATG16L1 PROTECTS AGAINST INTESTINAL GVHD BY REGULATING INTERFERON SIGNALING AND EPITHELIAL CELL DEATH** 17:06 CEST
Y. Matsuzawa, United States

Q&A 17:13 CEST

OP205 **P53 ORCHESTRATES DNA DAMAGE-INDUCED STEM CELL REPRESSION VIA STING/IFN-I MEDIATED EPITHELIAL NECROPTOSIS** 17:18 CEST
H. Xiang, Germany

Q&A 17:25 CEST

GORD pathophysiology

Chair: A. Bredenoord, Netherlands

Chair: E.V. Savarino, Italy

OP206	THE DIAGNOSTIC VALUE OF DILATED INTERCELLULAR SPACES OF ESOPHAGEAL EPITHELIUM IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE V. Gorgulu, Turkey	16:30 CEST
	Q&A	16:37 CEST
OP207	THE PATHOPHYSIOLOGY OF NON-EROSIVE REFLUX DISEASE (NERD) IS DIFFERENT IN CHILDREN COMPARED TO ADULTS IN REGARDS TO OESOPHAGEAL MUCOSA INTEGRITY AND INNERVATION K. Nikaki, United Kingdom	16:42 CEST
	Q&A	16:49 CEST
OP208	LACK OF SIGNIFICANT DIFFERENCES IN SOMATIZATION, ANXIETY, DEPRESSION AND FEAR OF PAIN LEVELS ACROSS THE GASTRO-OESOPHAGEAL REFLUX DISEASE SPECTRUM A. Geeraerts, Belgium	16:54 CEST
	Q&A	17:01 CEST
OP209	IS SLEEVE GASTRECTOMY A MODEL TO STUDY GASTROESOPHAGEAL REFLUX PATHOPHYSIOLOGY? THE EFFECTS ON ESOPHAGEAL FUNCTION S. Tolone, Italy	17:06 CEST
	Q&A	17:13 CEST
OP210	INTER-REVIEWER VARIABILITY IN ANALYSIS OF REFLUX EPISODES AND POST-REFLUX SWALLOW INDUCED PERISTALTIC WAVE ON PH-IMPEDANCE STUDIES: THE WINGATE CONSENSUS B. Rogers, United States	17:18 CEST
	Q&A	17:25 CEST

Epigastric pain

Expert/Chair: A. Smout, Netherlands

Expert: M. Fox, Switzerland

Expert: J. Keller, Germany

Expert: J. Tack, Belgium

Oesophageal motility disorders: What's new in 2020?

Chair: R. Tutuian, Switzerland

Chair: F. Zerbib, France

Chair: R.S. Penagini, Italy

IP246	EGJ outflow obstruction: Is it clinically relevant? Pro and Con S. Roman, France	18:00 CEST
	Q&A	18:10 CEST
IP247	Oesophageal provocation tests: Useful or useless? A. Bredenoord, Netherlands	18:20 CEST
	Q&A	18:30 CEST
IP248	Ineffective oesophageal motility: Is it clinically relevant? D. Sifrim, United Kingdom	18:40 CEST
	Q&A	18:50 CEST